Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market
NBER Working Paper No. 20005
---- Acknowledgements ----
The authors would like to thank Derek Neal and workshop participants at the American Law & Economics Association Meetings, the Conference on Empirical Legal Studies, Harvard Medical School, NBER Health Care Group Spring Meeting and Summer Institute, Rice University, UCLA, and the University of Chicago. Drs. Lakdawalla and Seabury thank the National Institute on Aging (1RC4AG039036 and 1P01AG033559) for financial support. Mr. Malani thanks the financial support of the Samuel J. Kersten Faculty Fund and the Microsoft Fund at the University of Chicago Law School. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.
---- Disclosure of Financial Relationships for Darius N. Lakdawalla ----
Dr. Lakdawalla is a partner in Precision Health Economics LLC, a consulting firm that receives funding from pharmaceutical manufacturers whose behavior and products liability exposures are studied in this manuscript.
---- Disclosure of Financial Relationships for Anup Malani ----
Anup Malani thanks the Samuel J. Kersten Faculty Fund and the Microsoft Fund for financial support. Mr. Malani has served as a consultant for Precision Health Economics.
---- Disclosure of Financial Relationships for Seth A. Seabury ----
Dr. Seabury is a consultant for Precision Health Economics, a pharmaceutical consulting firm.